Cipla gets final nod from USFDA for migraine treatment nasal spray

"It has received final approval for its Abbreviated New Drug Application (ANDA) for Dihydroergotamine Mesylate nasal spray 4mg/mL from the United States Food and Drug Administration (USFDA) with a competitive generic therapy (CGT) designation," the company said in a filing to BSE.

from Moneycontrol Business News https://ift.tt/2LMnabr